Dissecting of develomental signaling pathways in bone development and osteosarcoma

Information

  • Research Project
  • 10004080
  • ApplicationId
    10004080
  • Core Project Number
    P20GM103620
  • Full Project Number
    5P20GM103620-08
  • Serial Number
    103620
  • FOA Number
    PAR-16-241
  • Sub Project Id
    6036
  • Project Start Date
    9/1/2013 - 11 years ago
  • Project End Date
    8/31/2023 - a year ago
  • Program Officer Name
  • Budget Start Date
    9/1/2020 - 4 years ago
  • Budget End Date
    8/31/2021 - 3 years ago
  • Fiscal Year
    2020
  • Support Year
    08
  • Suffix
  • Award Notice Date
    9/9/2020 - 4 years ago
Organizations

Dissecting of develomental signaling pathways in bone development and osteosarcoma

PROJECT SUMMARY The goal of this project is to understand developmental signaling pathways (DSPs) that are regulated by human cancer driver mutations in premalignant osteoblast progenitor (POP) and osteogenic sarcoma (OS) cells. Human OS represents a deadly skeletal malignancy found predominantly in children. The clinical outcomes for OS patients with recurrent tumors, or metastatic spread, are devastating. Elucidating OS biology is essential for developing effective new treatments. Several lines of evidence suggest that tumor protein p53 (TP53) mutations are major drivers in OS patients with Li- Fraumeni familial cancer syndrome, and in most of sporadic OS patients. It is unknown, however, how aberrant p53-regulated DSPs promote the proliferation and transformation of POP cells, as well as maintain self-renewal of OS stem cell and metastasis. Along with our collaborators, we have developed several authentic, genetically engineered mouse models of OS tumors that recapitulate the defining feature of human OS, which include cytogenetic complexity, gene expression signatures, histology, and metastatic behavior. These models provide a powerful tool for understanding the aforementioned clinical challenge and for developing novel therapeutic strategies. Our preliminary studies in mice and human OS cells found a connection between DSPs and tumorigenesis in the transformation of POP cells to their malignant counterpart. Validating those findings will significantly contribute to clinical applications. Based on these findings, we hypothesize that DSPs downstream of driver mutations play a critical role in the POP and OS population; moreover, perturbation of the crosstalk between drivers and DSPs may contribute to the pathogenesis of OS and cancer therapy. We will test this hypothesis through three specific aims. Aim1. What is the role of DSPs regulated by p53 loss of function (p53 LOF) in the development of OS? Aim2. Do DSPs play a critical role in the development of cells of POP and OS driven by Notch gain of function (Notch GOF)? With the completion of this work, we will have a more complete understanding of the molecular mechanism underlying the action of driver-regulated DSPs on POP and OS cells.

IC Name
NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES
  • Activity
    P20
  • Administering IC
    GM
  • Application Type
    5
  • Direct Cost Amount
    186719
  • Indirect Cost Amount
    119485
  • Total Cost
  • Sub Project Total Cost
    306204
  • ARRA Funded
    False
  • CFDA Code
  • Ed Inst. Type
  • Funding ICs
    NIGMS:306204\
  • Funding Mechanism
    RESEARCH CENTERS
  • Study Section
    ZGM1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    SANFORD RESEARCH/USD
  • Organization Department
  • Organization DUNS
    050113252
  • Organization City
    SIOUX FALLS
  • Organization State
    SD
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    571040569
  • Organization District
    UNITED STATES